HIPPOCRATES

Health initiatives in psoriasis and psoriatic arthritis consortium European states
HIPPOCRATES logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 20
Grant agreement number
101007757

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
10 210 993
EFPIA in kind
11 035 000
Total Cost
21 245 993

Summary

Psoriasis is an autoimmune disease that primarily affects the skin. However, 20-30 % of people with psoriasis develop a condition called psoriatic arthritis. Symptoms of psoriatic arthritis include pain, joint stiffness and fatigue, and it can dramatically impact the quality of life of those affected. Today, psoriatic arthritis is very hard to diagnose, and it is not possible to predict which psoriasis patients will go on to develop psoriatic arthritis.

The aim of HIPPOCRATES is to deliver knowledge and tools that will make it easier to spot the psoriasis patients who are at greatest risk of developing psoriatic arthritis, and diagnose them faster. In addition, the team hopes to make it easier to predict how fast a patient’s condition is likely to worsen, and which treatments are most likely to be effective for them. Finally, the team plans to probe the molecular basis of psoriatic arthritis – information that will aid in the development of much-needed new drugs to treat the condition.

The project will do all of this by drawing together data from existing psoriatic arthritis studies and establishing a library of clinical samples. They will also carry out a new study which will follow 25 000 people with psoriasis to see which ones develop psoriatic arthritis. The project will use machine learning and other artificial intelligence techniques to assist in the analysis of the data. Patients are at the heart of the consortium and will be involved in all aspects of the project’s work.

Ultimately, by speeding up diagnosis and paving the way for personalised treatments, HIPPOCRATES will improve the quality of life of people living with psoriatic arthritis.

Participants Show participants on map

EFPIA companies
  • Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • UCB Biopharma, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands
  • European League Against Rheumatism, Kilchberg, Switzerland
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Fundacio Clinic Per A La Recerca Biomedica, Barcelona, Spain
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • King'S College London, London, United Kingdom
  • Kungliga Tekniska Hoegskolan, Stockholm, Sweden
  • Region Hovedstaden, Hilleroed, Denmark
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • Stichting Group For Research And Assessment Of Psoriasis And Psoriatic Arthritis Eu, Rijsenhout, Netherlands
  • The European Institute For Innovation Through Health Data, Gent, Belgium
  • The University Of Manchester, Manchester, United Kingdom
  • Universita Cattolica Del Sacro Cuore, Milan, Italy
  • Universitatsklinikum Erlangen, Erlangen, Germany
  • University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland
  • University Of Glasgow, Glasgow, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Vib Vzw, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Atturos Limited, Limerick Clare, Ireland
  • Eurice European Research And Project Office GMBH, Saarbrücken, Germany
  • Neoteryx Limited, Warrington, United Kingdom
  • Oxford Biodynamics Plc, Oxford, United Kingdom
Third parties
  • Hospital Clinic De Barcelona, Barcelona, Spain
Project coordinator
Oliver Fitzgerald
University College Dublin, National University Of Ireland, Dublin